What happened
The fourth morning session of the 2026 national basic medical insurance drug catalog negotiation and commercial insurance innovative drug catalog price consultation officially started at around 8 a.m. today.
Reporters at the scene observed representatives from about 20 companies, including Kelun Pharma, Luye Pharma, Chia Tai Tianqing, Shenwei Pharma, Jiangxi Yaodu Zhangshu, Weikang Pharma, Tasly, and Jilin Aodong, queuing to enter the venue.
This marks the second time during the negotiations that a batch of traditional Chinese medicine companies and Western medicine companies entered negotiations simultaneously, following the first day.
Why it matters
The simultaneous entry of both traditional Chinese medicine and Western medicine companies suggests a broad scope of drug categories under review, potentially impacting a wide range of treatments and patient access.
The participation of multiple companies indicates high competition and interest in securing favorable reimbursement terms, which could influence drug pricing and market dynamics.
Key facts
The fourth morning session of the 2026 national medical insurance drug catalog negotiations began at around 8 a.m. today.
About 20 companies, including Kelun Pharma, Luye Pharma, Chia Tai Tianqing, Shenwei Pharma, Jiangxi Yaodu Zhangshu, Weikang Pharma, Tasly, and Jilin Aodong, were observed entering the venue.
This is the second time during the negotiations that both traditional Chinese medicine and Western medicine companies entered simultaneously.
What to watch next
Observers will be watching for the outcomes of these negotiations, particularly which drugs are included in the final catalog and at what prices.
The progress of commercial insurance innovative drug catalog price consultations may also be a key focus, as it could set precedents for future negotiations.